Biotechnology Archives - InvestorWire (IW)

Monday Apr 29, 2024 - 11:15 am

Astiva Health Inc. Innovative Holistic Approach Underscores Understanding That Effective Primary Care Is Foundational

PCPs play pivotal role in successful healthcare approach Evidence shows that primary care helps prevent illness and death Astiva Health has established a healthcare ecosystem where best PCPs are rewarded for expertise, commitment The importance of primary care in a successful healthcare approach has been clearly shown through decades of research. Astiva Health is dedicated to enhancing the quality of medical care through a strong…

Thursday Mar 28, 2024 - 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Discusses 2023 Progress and 2024 Plans in Corporate Update

Longeveron recently released its full-year results for the period ended December 31, 2023, and provided a corporate update The update outlined the company’s plans to prioritize the development of Lomecel-B(TM) in Hypoplastic Left Heart Syndrome (“HLHS”), a rare, pediatric congenital heart condition characterized by an underdeveloped left side of the heart Longeveron plans to complete the enrollment in the ELPIS II trial for HLHS in…

Thursday Mar 28, 2024 - 9:00 am

Astrotech Corp. (NASDAQ: ASTC) and AgLAB Inc. Use Mass Spectrometer Technology to Significantly Enhance Hemp and Cannabis Production Yield and Profit

The cannabinoid market value in 2023 was $22.23 billion and is expected to grow at a CAGR of 15.3%, resulting in an estimated market value of $60.36 billion The global mass spectrometry market will reach $6.77 billion in 2024 and is expected to grow at a CAGR of 6.25%, reaching $9.17 billion by 2029. Astrotech and subsidiary AgLAB Inc. are using mass spectrometry to boost…

Tuesday Mar 26, 2024 - 9:00 am

Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS

Clene’s recently released 2023 financial and operational updates highlight the company’s developments for the treatment of amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis CNM-Au8(R) functions as a neuroprotective and remyelinating therapy in neurodegenerative diseases Recent data from the randomized, double-blind, placebo-controlled HEALEY-ALS Platform Trial and its open-label extension, reported by Clene in December 2023, revealed encouraging outcomes on survival and delayed clinical worsening Clene recently…

Thursday Mar 21, 2024 - 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium

Autism (“ASD”) is a global problem, with no generally accepted treatment. In the UK alone, between 1998 and 2018, research has found a greater than 780% increase in the number of autism cases PaxMedica is focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of ASD and other serious conditions with intractable neurologic symptoms The ASD therapeutics market was valued at $2.01…

Monday Mar 18, 2024 - 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to Its Board of Directors

CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally The company believes Ms. Mahery’s guidance, insight, and vast pharma industry network will indeed be invaluable as the company advances Berubicin, its flagship drug…

Tuesday Feb 06, 2024 - 9:00 am

Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS

Clene recently reported new results from the open-label, long-term extension (“LTE”) of the VISIONARY-MS trial, involving participants with stable relapsing Multiple Sclerosis (“MS”) through week 144 (over 2.75 years) after the initial randomization Results from the 48-week double-blind period showed statistically significant improvements in vision (primary endpoint), as well as a combined improvement in cognition, walking speed, upper extremity function, and vision (secondary endpoint) with…

Tuesday Jan 23, 2024 - 9:45 am

Astrotech Corp. (NASDAQ: ASTC) Subsidiary AgLAB: Breakthrough Technology For Ag-Distillers

Astrotech subsidiary AgLAB demonstrates the capability of significant improvements in yields for large scale producers of hemp and cannabis CBD-THC oils using breakthrough mass spectrometry technology The company’s AgLAB 1000-D2(TM) mass spectrometer and the Maximum Value Process(TM) testing method (“AgLAB MVP(TM)”) allows large-scale distillers to analyze oils during processing, and make real-time adjustments to boost yields and potencies Field trials resulted in improved ending-weight yields…

Monday Dec 11, 2023 - 11:15 am

SOHM Inc. (SHMN) Taps into UACI’s Robust Resources and Specialized Infrastructure for ABBIE Advancement

SOHM, a generic drug manufacturing and distributing innovator, announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its ABBIE platform In the arrangement, SOHM will establish offices and a wet lab bench, taking advantage of UACI’s robust and specialized infrastructure SOHM’s management is optimistic about the collaboration and is confident that this is but the first step…

Monday Dec 11, 2023 - 9:00 am

Astrotech Corp. (NASDAQ: ASTC) Is ‘One to Watch’

In November 2023, the company announced a purchase order from a Romanian company for seven TRACER 1000 ETDs to be deployed in a European airport Astrotech announced in June 2023 that its board unanimously rejected an unsolicited acquisition proposal from BML Investment Partners In May 2023, the company announced a purchase order from a Romanian company for 17 TRACER 1000 ETDs, to be delivered during…

Friday Dec 08, 2023 - 9:00 am

The 2023 Nobel Prize in Chemistry’s Spotlight on Nanotechnology Shines Light on Clene Inc. (NASDAQ: CLNN) Efforts to Develop Catalytically Active Nanoparticles

The 2023 Nobel Prize in Chemistry, awarded to Moungi G. Bawendi, Louis E. Brus, and Aleksey Yekimov for their efforts in discovering and synthesizing quantum dots, recognizes the power of nanotechnology Nanoscience is the study of structures and molecules whose sizes range between 1 and 100 nm, while nanotechnology is the technology that utilizes nanoscience in practical applications The applications of nanotechnology are wide-ranging, from…

Thursday Nov 16, 2023 - 9:45 am

Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program

Clene recently released its financial results for the third quarter ended September 30, 2023, and provided recent operating highlights for its ALS clinical program The ALS clinical program includes two independent studies evaluating the safety and efficacy of the company’s lead investigational product CNM-Au8(R) The 24-month long-term data cut from the open-label extension of the RESCUE-ALS study showed a significant median survival benefit of 19.3…

Tuesday Nov 14, 2023 - 9:30 am

PaxMedica Inc. (NASDAQ: PXMD) Is Hoping to Boost Patient Independence with Potential ASD Treatment Amid Growing Prevalence Rates

PaxMedica is developing PAX-101, which utilizes the company’s proprietary source of suramin sodium, for the treatment of ASD (Autism Spectrum Disorder) There is no FDA-approved treatment for the core symptoms of autism, even though the rates of autism spectrum disorder have jumped significantly from 2000 to 2020 ASD is characterized by deficits in social communication, restricted and repetitive patterns of behavior, and significant impairment in…

Thursday Oct 19, 2023 - 10:30 am

SOHM, Inc. (SHMN) Completes Acquisition of ABBIE Gene-editing Tech, Begins Preparations to Commercialize Solutions for Heart Disease

Generic drug manufacturer and distributor SOHM has completed the LOI process to acquire stem cell gene-editing technology ABBIE from CGA Intellectual Holdings Inc. The company expects the technology to provide it with commercialization revenues as it builds a solution for gene-enhanced stem cells that can be used to treat a number of diseased organs, beginning with heart ailments The edited-gene cells are expected to be…

Thursday Oct 12, 2023 - 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) CEO Presents ASD Pipeline and Corporate Presentation at H.C. Wainwright 25th Annual Global Investment Conference

Howard Weisman presented PaxMedica’s goals and plans to investors at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 The presentation defined the company’s intention to generate significant funding for its ASD program by first gaining approval for suramin sodium in the treatment of a rare and deadly infection using the same drug The global ASD treatment market was valued at $2.02…

Wednesday Oct 04, 2023 - 9:45 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Secures $1.33 Million from Registered Direct Offering to Boost Commercial Development

Scinai Immunotherapeutics recently announced the closing of a registered direct offering, raising $1.33 million in gross proceeds The company intends to use the net proceed from the offering for, among others, research and development On its R&D agenda is the development and commercialization of novel innovative NanoAbs targeting a wide range of diseases with known and validated antibody drug targets This strategic approach is expected…

Monday Oct 02, 2023 - 9:00 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Finalizes Rebrand to Reflect New Strategic Direction, Diversification

Scinai Immunotherapeutics, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, recently finalized a major rebrand, changing its corporate name from BiondVax Pharmaceuticals The rebrand is part of a series of steps to better reflect the company’s new direction and new developments aimed at new scientific breakthroughs Amir Reichman took over as CEO in March 2021 and together with the Board of…

Friday Sep 29, 2023 - 11:15 am

PaxMedica Inc. (NASDAQ: PXMD) Releases Compelling Video: Progress Report on ASD and Hope for the Future

Autism Spectrum Disorder (“ASD”) has seen a staggering fourfold increase in the United States over the past two decades PaxMedica proudly stands as the sole publicly traded U.S. company singularly dedicated to addressing the challenges posed by Autism Our pioneering lead product, PAX-101, has shown significant promise in alleviating core Autism symptoms during early trials In 2024, we're poised to submit a New Drug Application…

Thursday Sep 28, 2023 - 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Presents Achievements, Goals at H.C. Wainwright 25th Annual Global Investment Conference in New York City

RVL Pharmaceuticals CEO Brian Markison participated in a fireside chat and hosted one-on-one investor meetings during the conference The company's primary focus is the commercialization of UPNEEQ(R), which is available by prescription for treating acquired blepharoptosis or low-lying eyelids in adults The global medical aesthetics market was estimated at $13.9 billion in 2022 and is expected to reach $23.4 billion by 2027, growing at a…

Thursday Sep 28, 2023 - 9:00 am

Clene Inc. (NASDAQ: CLNN) Is ‘One to Watch’

In June 2023, The Lancet’s eClinicalMedicine journal published combined detailed analyses of Clene’s Phase 2 RESCUE-ALS study and its open-label extension trial In June 2023, Clene announced the closing of a $40 million underwritten public offering with potentially up to an additional $130 million from future warrant exercises As of January 2023, Clene had more than 150 issued patents worldwide and approximately 20 patents pending worldwide on…

Wednesday Sep 27, 2023 - 9:45 am

Longeveron Inc. (NASDAQ: LGVN) Eyeing Global HLHS, in addition to Alzheimer’s Disease, and Aging-Related Frailty Treatment Markets with Lomecel-B(TM), its Lead Investigational Product

Longeveron’s study ELPIS I demonstrated 100% survival and heart transplant-free for up to 5 years of age All ten patients enrolled in the study were monitored for at least 3.5 years after treatment with Lomecel-B(TM), the company’s lead investigational product Longeveron’s study results show Lomecel-B(TM)’s potential, not just for the potential treatment of HLHS but also for Alzheimer’s disease and Aging-related Frailty Longeveron (NASDAQ: LGVN),…

Monday Sep 25, 2023 - 10:30 am

Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study

CNS Pharmaceuticals is conducting a global clinical trial to evaluate its flagship drug candidate for treating glioblastoma, a deadly brain cancer CNS has enrolled 200 of its planned 243 patients for its clinical trial roster, and anticipates filling out the remainder of patients by year’s end The company is also preparing the interim study analysis for release by year’s end, now that more than 50…

Wednesday Sep 20, 2023 - 11:15 am

Renovaro BioSciences Inc. (NASDAQ: RENB) Targets Pancreatic Cancer Solution Through Work With GEDI Cube AI Platform, NVIDIA Resources

California-based cancer fighter Renovaro BioSciences is turning the power of its immune system-promoting technology to the fight against pancreatic cancer and other illnesses that tend to leave patients with a short life expectancy once they are diagnosed Renovaro recently announced a binding, exclusive letter of intent (“LOI”) to add GEDI Cube’s artificial intelligence (“AI”) data mining technology to its fight against such cancers GEDI Cube…

Wednesday Sep 20, 2023 - 9:00 am

Generic Drug Manufacturer SOHM, Inc. (SHMN) Building Regenerative Medicine Platform with LOI for Gene Editing Technology

U.S.-based generic drug developer SOHM is working to build its product pipeline through registration for distribution in several states and the planned establishment of its own product manufacturing plant in Southern California SOHM is also focused on developing a regenerative medicine portfolio, having issued an LOI recently in its bid to acquire the gene editing technology ABBIE from CGA Intellectual Holdings Inc. ABBIE is a…

Wednesday Sep 13, 2023 - 10:30 am

PaxMedica Inc. (NASDAQ: PXMD) Is ‘One to Watch’

PaxMedica recently announced positive top line results from its PAX-101 Phase 3 African Sleeping Sickness Study, paving the way for an expected New Drug Application filing in 2024 The company granted exclusive pharmacy distribution for PAX-101 to Vox Nova LLC, the first purpose-built limited distribution specialty pharmacy benefit manager for people with ASD PaxMedica submitted PAX-101 Clinical Trial Request to the South African Health Products…

Tuesday Sep 12, 2023 - 9:45 am

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) NanoAbs for Psoriasis Treatment May Offer Significant Advantages Over Apogee

About 125 million people worldwide have psoriasis, a chronic disease where the immune system becomes overactive, causing skin cells to multiply too quickly The psoriasis treatment market is expected to reach $48.33 billion by 2030, driven by an increase in diagnosed patients and the prevalence of skin disorders in developed nations Scinai’s NanoAbs targeting the IL-17 family of cytokines, which have shown promise in treating…

Monday Sep 11, 2023 - 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) to Attend H.C. Wainwright 25th Annual Global Investment Conference and Discuss UPNEEQ(R) for Treating Acquired Blepharoptosis

RVL Pharmaceuticals' CEO Brian Markison and COO JD Schaub will participate in a fireside chat and 1-on-1 investor meetings on Tuesday, September 12, 2023, during this year's H.C. Wainwright Annual Global Investment Conference in New York City The company will discuss UPNEEQ(R) and its use as the first non-surgical treatment option approved by the FDA for acquired blepharoptosis RVL Pharmaceuticals plans to continue marketing to…

Friday Sep 08, 2023 - 10:30 am

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Is ‘One to Watch’

In July 2023, LSDI launched Twilight, a new sleep aid product The company in July 2023 announced its acquisition of SANA-013 from Wesana Health; SANA-013 is being developed for the treatment of several mental health and central nervous system conditions LSDI in May 2023 launched its new Mindful product line designed to enhance well-being and promote a mindful approach to life Also in May 2023,…

Friday Sep 08, 2023 - 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study

CNS Pharmaceuticals recently announced updated results from its pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin The novel anthracycline demonstrated its capability to be an innovative potential treatment option for GBM 151 patients have been enrolled in the study, marking the data cutoff point and a significant milestone toward reporting topline results before the end of the year Based on the…

Thursday Sep 07, 2023 - 9:30 am

The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction

Lucy Scientific Beats MindMed and Seelos Therapeutics to the Punch Lucy Scientific Discovery (NASDAQ: LSDI) (“Lucy” or the “Company), a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses, just announced the acquisition of the Intellectual Property of High Times, its Licensing Agreements and Royalty Streams in all-stock transaction. This was a brilliant strategic business move. With first movers in the “Mind…

Tuesday Sep 05, 2023 - 9:45 am

Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline

U.S.-based gene therapy developer Genprex, Inc. is developing new therapies for fighting cancer tumors and diabetes The company’s gene therapies for battling types 1 and 2 diabetes use a simple endoscopic procedure to introduce select insulin-boosting genes directly to the pancreas to combat insulin decline factors in the body The company is working with research collaborators at the University of Pittsburgh (Pitt) and recently announced…

Wednesday Aug 30, 2023 - 9:45 am

Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation Amid Preparations for Planned Acclaim-3 Clinical Trial

Genprex recently received orphan drug designation for its lead drug candidate REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid) for the treatment of small cell lung cancer (“SCLC”) The company also celebrated receipt of its third Fast Track Designation (“FTD”), granted by the FDA, this time for REQORSA Immunogene Therapy, in combination with Tecentriq in patients with extensive stage small cell lung cancer (“ES-SCLC”) The orphan drug designation…

Friday Aug 25, 2023 - 9:45 am

Renovaro BioSciences Inc. (NASDAQ: RENB) Aims to Unlock Potential Treatments and Cures for Serious Infectious Diseases and Cancer

Renovaro’s current product development pipeline includes a variety of treatment candidates spanning cancer, HIV, and HBV Renovaro’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat The company recently entered into an LOI with GEDi Cube that could enhance the efficacy of upcoming trials and speed up delivery results As an…

Wednesday Aug 23, 2023 - 9:45 am

RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’

For the quarter ended June 30, 2023, RVLP reported net sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year period; this strategy is designed to extend cash runway for future business development and changes in the company’s marketing mix The company’s marketing partner, Santen, has commenced the required registrational trial for UPNEEQ(R) in Japan…

Wednesday Aug 23, 2023 - 9:00 am

Renovaro BioSciences Inc. (NASDAQ: RENB), Immunotherapy Biotech Company, Announces Intention to Unite With AI Tech Developer GEDi Cube, Seen as Major Multiplier Effect in the Fight Against Cancer

Combination of advanced AI machine learning technology and proven immunotherapy technology seen as “future of medicine” Demonstrated success that both companies have shown with their innovative developments is expected to expand synergistically Potential applications against variety of cancers The announcement of a binding and exclusive letter of intent to merge, between two of the most innovative companies in their respective fields, is seen as representing…

Friday Aug 18, 2023 - 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Advances NanoAb Therapy as IL-17 Drug Candidate for Psoriasis Treatment

Similar business model but different antibody therapies for psoriasis treatment, BiondVax uses NanoAbs while Apogee Therapeutics, Inc. uses conventional mAbs BiondVax NanoAbs provide superior benefits not seen in mAb therapies, including new routes of administration, higher affinity, better binding, and a higher level of stability at room temperature Apogee recently went public at $500 million pre-money, raising $300 million in an upsized deal, and has…

Monday Aug 14, 2023 - 11:15 am

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Alpaca-Derived Nanobodies for Potential Treatment of Diseases Underserved by Current Therapeutics

Innovative nanobody therapeutics could deliver substantial competitive advantages in both cost and efficacy when compared to traditional monoclonal antibody therapies The biologics market was valued at $366.5 billion in 2021 and is expected to grow to a value of $719.94 billion by 2030 The monoclonal antibodies market was valued at $210.06 billion in 2022, and it is expected to reach $494.53 billion by 2030 The…

Monday Aug 14, 2023 - 9:00 am

Renovaro BioSciences Inc. (NASDAQ: RENB) Is ‘One to Watch’

In June 2023, Renovaro announced that a potential IND application for its innovative cancer platform is on track for early 2024 FDA submission The company in March 2023 announced proof-of-concept for its proprietary technology to treat pancreatic tumors In August 2023, Renovaro announced its entry into a Letter of Intent to merge with GEDi Cube International Ltd. with the aim of accelerating diagnosis, enhancing treatment…

Friday Jul 28, 2023 - 9:45 am

Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China with Chinese Patent

Genprex recently received a patent in China covering the use of its drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers The REQORSA-Keytruda drug combination is the subject of Genprex’s ongoing Acclaim-2 clinical trial, which targets patients with advanced, metastatic non-small cell lung cancer whose disease progressed after treatment with Keytruda The company has received patent protection for…

Wednesday Jul 26, 2023 - 9:45 am

M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

BiondVax, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, was featured in a recent analyst report reiterating a Buy recommendation and a $70 target price The report discussed Eli Lilly’s announcement of a definitive agreement to acquire DICE Therapeutics for approximately $2.4 billion as evidence of the potential value of BiondVax in this segment of the therapeutics market DICE Therapeutics is…

Articles

Articles Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions